{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T12:35:43Z","timestamp":1758630943907,"version":"3.40.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,7,21]],"date-time":"2018-07-21T00:00:00Z","timestamp":1532131200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2018,7,21]],"date-time":"2018-07-21T00:00:00Z","timestamp":1532131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s00277-018-3448-9","type":"journal-article","created":{"date-parts":[[2018,7,20]],"date-time":"2018-07-20T22:06:00Z","timestamp":1532124360000},"page":"2373-2380","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Characteristics of pulmonary complications in non-Hodgkin\u2019s lymphoma patients treated with rituximab-containing chemotherapy and impact on survival"],"prefix":"10.1007","volume":"97","author":[{"given":"Kimberly","family":"Keefer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regis","family":"Bender","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Sivik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2260-2005","authenticated-orcid":false,"given":"Andry","family":"Van de Louw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,21]]},"reference":[{"issue":"1","key":"3448_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3322\/caac.21166","volume":"63","author":"R Siegel","year":"2013","unstructured":"Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1):11\u201330. https:\/\/doi.org\/10.3322\/caac.21166","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"3448_CR2","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346(4):235\u2013242. https:\/\/doi.org\/10.1056\/NEJMoa011795","journal-title":"N Engl J Med"},{"issue":"2","key":"3448_CR3","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1200\/JCO.2001.19.2.389","volume":"19","author":"JM Vose","year":"2001","unstructured":"Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Gilman P, Lowe A, Kunkel LA, Fisher RI (2001) Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin\u2019s lymphoma. J Clin Oncol 19(2):389\u2013397. https:\/\/doi.org\/10.1200\/JCO.2001.19.2.389","journal-title":"J Clin Oncol"},{"issue":"1","key":"3448_CR4","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1200\/JCO.1999.17.1.268","volume":"17","author":"MS Czuczman","year":"1999","unstructured":"Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, LoBuglio AF, Jonas C, Klippenstein D, Dallaire B, Varns C (1999) Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17(1):268\u2013276. https:\/\/doi.org\/10.1200\/JCO.1999.17.1.268","journal-title":"J Clin Oncol"},{"issue":"2","key":"3448_CR5","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1164\/ajrccm\/146.2.485","volume":"146","author":"K Jules-Elysee","year":"1992","unstructured":"Jules-Elysee K, Stover DE, Yahalom J, White DA, Gulati SC (1992) Pulmonary complications in lymphoma patients treated with high-dose therapy autologous bone marrow transplantation. Am Rev Respir Dis 146(2):485\u2013491. https:\/\/doi.org\/10.1164\/ajrccm\/146.2.485","journal-title":"Am Rev Respir Dis"},{"issue":"5","key":"3448_CR6","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.3109\/10428194.2014.922181","volume":"56","author":"C Algrin","year":"2015","unstructured":"Algrin C, Faguer S, Lemiale V, Lengline E, Boutboul D, Amorim S, Galicier L, Canet E, Thieblemont C, Azoulay E (2015) Outcomes after intensive care unit admission of patients with newly diagnosed lymphoma. Leuk Lymphoma 56(5):1240\u20131245. https:\/\/doi.org\/10.3109\/10428194.2014.922181","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"3448_CR7","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.3109\/10428194.2015.1106537","volume":"57","author":"P Wohlfarth","year":"2016","unstructured":"Wohlfarth P, Carlstrom A, Staudinger T, Clauss S, Hermann A, Rabitsch W, Bojic A, Skrabs C, Porpaczy E, Schiefer AI, Valent P, Knobl P, Agis H, Hauswirth A, Jager U, Kundi M, Sperr WR, Schellongowski P, Arbeitsgruppe fur hamato-onkologische Intensivmedizin der Osterreichischen Gesellschaft fur Internistische und Allgemeine Intensivmedizin und N (2016) Incidence of intensive care unit admission, outcome and post intensive care survival in patients with diffuse large B-cell lymphoma. Leuk Lymphoma 57(8):1831\u20131838. https:\/\/doi.org\/10.3109\/10428194.2015.1106537","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"3448_CR8","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.3109\/10428194.2014.963075","volume":"56","author":"G Salmasi","year":"2015","unstructured":"Salmasi G, Li M, Sivabalasundaram V, Panzarella T, Tsang R, Kukreti V, Crump M, Kuruvilla J (2015) Incidence of pneumonitis in patients with non-Hodgkin lymphoma receiving chemoimmunotherapy with rituximab. Leuk Lymphoma 56(6):1659\u20131664. https:\/\/doi.org\/10.3109\/10428194.2014.963075","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"3448_CR9","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1080\/10428190902919200","volume":"50","author":"D Kalkanis","year":"2009","unstructured":"Kalkanis D, Stefanovic A, Paes F, Escalon MP, Serafini A, Lossos IS (2009) [18F]-fluorodeoxyglucose positron emission tomography combined with computed tomography detection of asymptomatic late pulmonary toxicity in patients with non-Hodgkin lymphoma treated with rituximab-containing chemotherapy. Leuk Lymphoma 50(6):904\u2013911. https:\/\/doi.org\/10.1080\/10428190902919200","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"3448_CR10","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1002\/ajh.20910","volume":"82","author":"SA Wagner","year":"2007","unstructured":"Wagner SA, Mehta AC, Laber DA (2007) Rituximab-induced interstitial lung disease. Am J Hematol 82(10):916\u2013919. https:\/\/doi.org\/10.1002\/ajh.20910","journal-title":"Am J Hematol"},{"issue":"3","key":"3448_CR11","doi-asserted-by":"publisher","first-page":"546","DOI":"10.3109\/10428190903518303","volume":"51","author":"C Vulsteke","year":"2010","unstructured":"Vulsteke C, Dierickx D, Verbeken E, Wolter P, Thomas J, Schoffski P (2010) Rituximab-induced fatal interstitial pneumonitis: case report. Leuk Lymphoma 51(3):546\u2013548. https:\/\/doi.org\/10.3109\/10428190903518303","journal-title":"Leuk Lymphoma"},{"issue":"5\u20136","key":"3448_CR12","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1159\/000327681","volume":"87","author":"A Zayen","year":"2011","unstructured":"Zayen A, Rais H, Rifi H, Ouarda M, Afrit M, Cherif A, Mezline A (2011) Rituximab-induced interstitial lung disease: case report and literature review. Pharmacology 87(5\u20136):318\u2013320. https:\/\/doi.org\/10.1159\/000327681","journal-title":"Pharmacology"},{"issue":"1","key":"3448_CR13","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3904\/kjim.2010.25.1.86","volume":"25","author":"KH Lim","year":"2010","unstructured":"Lim KH, Yoon HI, Kang YA, Lee KW, Kim JH, Bang SM, Lee JH, Lee CT, Lee JS (2010) Severe pulmonary adverse effects in lymphoma patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus rituximab. Korean J Intern Med 25(1):86\u201392. https:\/\/doi.org\/10.3904\/kjim.2010.25.1.86","journal-title":"Korean J Intern Med"},{"issue":"9","key":"3448_CR14","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1080\/10428190802270886","volume":"49","author":"X Liu","year":"2008","unstructured":"Liu X, Hong XN, Gu YJ, Wang BY, Luo ZG, Cao J (2008) Interstitial pneumonitis during rituximab-containing chemotherapy for non-Hodgkin lymphoma. Leuk Lymphoma 49(9):1778\u20131783. https:\/\/doi.org\/10.1080\/10428190802270886","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"3448_CR15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s12149-007-0089-9","volume":"22","author":"T Kazama","year":"2008","unstructured":"Kazama T, Faria SC, Uchida Y, Ito H, Macapinlac HA (2008) Pulmonary drug toxicity: FDG-PET findings in patients with lymphoma. Ann Nucl Med 22(2):111\u2013114. https:\/\/doi.org\/10.1007\/s12149-007-0089-9","journal-title":"Ann Nucl Med"},{"issue":"6","key":"3448_CR16","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.3109\/10428190109097760","volume":"42","author":"S Kanelli","year":"2001","unstructured":"Kanelli S, Ansell SM, Habermann TM, Inwards DJ, Tuinstra N, Witzig TE (2001) Rituximab toxicity in patients with peripheral blood malignant B-cell lymphocytosis. Leuk Lymphoma 42(6):1329\u20131337. https:\/\/doi.org\/10.3109\/10428190109097760","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"3448_CR17","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1093\/rheumatology\/ker290","volume":"51","author":"AV Hadjinicolaou","year":"2012","unstructured":"Hadjinicolaou AV, Nisar MK, Parfrey H, Chilvers ER, Ostor AJ (2012) Non-infectious pulmonary toxicity of rituximab: a systematic review. Rheumatology (Oxford) 51(4):653\u2013662. https:\/\/doi.org\/10.1093\/rheumatology\/ker290","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"3448_CR18","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1002\/pds.1587","volume":"17","author":"V Gonzalez","year":"2008","unstructured":"Gonzalez V, Salgueiro E, Jimeno FJ, Hidalgo A, Rubio T, Manso G (2008) Post-marketing safety of antineoplasic monoclonal antibodies: rituximab and trastuzumab. Pharmacoepidemiol Drug Saf 17(7):714\u2013721. https:\/\/doi.org\/10.1002\/pds.1587","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"3448_CR19","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s12185-008-0066-7","volume":"87","author":"D Ennishi","year":"2008","unstructured":"Ennishi D, Terui Y, Yokoyama M, Mishima Y, Takahashi S, Takeuchi K, Ikeda K, Tanimoto M, Hatake K (2008) Increased incidence of interstitial pneumonia by CHOP combined with rituximab. Int J Hematol 87(4):393\u2013397. https:\/\/doi.org\/10.1007\/s12185-008-0066-7","journal-title":"Int J Hematol"},{"issue":"11","key":"3448_CR20","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.3109\/10428190903258780","volume":"50","author":"H Katsuya","year":"2009","unstructured":"Katsuya H, Suzumiya J, Sasaki H, Ishitsuka K, Shibata T, Takamatsu Y, Tamura K (2009) Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma. Leuk Lymphoma 50(11):1818\u20131823. https:\/\/doi.org\/10.3109\/10428190903258780","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"3448_CR21","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1183\/09031936.00080209","volume":"35","author":"H Liote","year":"2010","unstructured":"Liote H, Liote F, Seroussi B, Mayaud C, Cadranel J (2010) Rituximab-induced lung disease: a systematic literature review. Eur Respir J 35(3):681\u2013687. https:\/\/doi.org\/10.1183\/09031936.00080209","journal-title":"Eur Respir J"},{"issue":"2","key":"3448_CR22","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1093\/annonc\/mdg070","volume":"14","author":"S Limat","year":"2003","unstructured":"Limat S, Demesmay K, Voillat L, Bernard Y, Deconinck E, Brion A, Sabbah A, Woronoff-Lemsi MC, Cahn JY (2003) Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin\u2019s lymphoma. Ann Oncol 14(2):277\u2013281","journal-title":"Ann Oncol"},{"issue":"2","key":"3448_CR23","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1148\/120.2.277","volume":"120","author":"R Filly","year":"1976","unstructured":"Filly R, Bland N, Castellino RA (1976) Radiographic distribution of intrathoracic disease in previously untreated patients with Hodgkin\u2019s disease and non-Hodgkin\u2019s lymphoma. Radiology 120(2):277\u2013281. https:\/\/doi.org\/10.1148\/120.2.277","journal-title":"Radiology"},{"issue":"1","key":"3448_CR24","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3324\/haematol.10564","volume":"92","author":"A Kolstad","year":"2007","unstructured":"Kolstad A, Holte H, Fossa A, Lauritzsen GF, Gaustad P, Torfoss D (2007) Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen. Haematologica 92(1):139\u2013140","journal-title":"Haematologica"},{"issue":"6","key":"3448_CR25","first-page":"1023","volume":"61","author":"SA Rosenberg","year":"1977","unstructured":"Rosenberg SA (1977) Validity of the Ann Arbor staging classification for the non-Hodgkin\u2019s lymphomas. Cancer Treat Rep 61(6):1023\u20131027","journal-title":"Cancer Treat Rep"},{"issue":"3","key":"3448_CR26","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1182\/blood-2003-04-1257","volume":"103","author":"SM Horwitz","year":"2004","unstructured":"Horwitz SM, Negrin RS, Blume KG, Breslin S, Stuart MJ, Stockerl-Goldstein KE, Johnston LJ, Wong RM, Shizuru JA, Horning SJ (2004) Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 103(3):777\u2013783. https:\/\/doi.org\/10.1182\/blood-2003-04-1257","journal-title":"Blood"},{"issue":"8","key":"3448_CR27","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.3324\/haematol.2013.100818","volume":"99","author":"JF Seymour","year":"2014","unstructured":"Seymour JF, Pfreundschuh M, Trneny M, Sehn LH, Catalano J, Csinady E, Moore N, Coiffier B, Investigators MS (2014) R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes. Haematologica 99(8):1343\u20131349. https:\/\/doi.org\/10.3324\/haematol.2013.100818","journal-title":"Haematologica"},{"issue":"8","key":"3448_CR28","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1038\/sj.bjc.6602504","volume":"92","author":"M Mohren","year":"2005","unstructured":"Mohren M, Markmann I, Jentsch-Ullrich K, Koenigsmann M, Lutze G, Franke A (2005) Increased risk of thromboembolism in patients with malignant lymphoma: a single-centre analysis. Br J Cancer 92(8):1349\u20131351. https:\/\/doi.org\/10.1038\/sj.bjc.6602504","journal-title":"Br J Cancer"},{"issue":"1","key":"3448_CR29","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s12032-017-1075-2","volume":"35","author":"K Mizia-Stec","year":"2017","unstructured":"Mizia-Stec K, Elzbieciak M, Wybraniec MT, Rozewicz M, Bodys A, Braksator W, Gasior Z, Gosciniak P, Hryniewiecki T, Kasprzak J, Wojtarowicz A, Zdziarska B, Plonska-Gosciniak E (2017) Chemotherapy and echocardiographic indices in patients with non-Hodgkin lymphoma: the ONCO-ECHO study. Med Oncol 35(1):14. https:\/\/doi.org\/10.1007\/s12032-017-1075-2","journal-title":"Med Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-018-3448-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3448-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3448-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T22:13:50Z","timestamp":1744150430000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-018-3448-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,21]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["3448"],"URL":"https:\/\/doi.org\/10.1007\/s00277-018-3448-9","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2018,7,21]]},"assertion":[{"value":"8 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in the studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required. This study was approved by the Pennsylvania State University Institutional Review Board (IRB number 5590), and informed consent was waived due to the retrospective design of the data collection.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}